Fate Therapeutics, Inc. (FATE) SEC Filings & Earnings Calls

Clinical-stage biotech with no approved products; high cash burn rate.

“Cash decrease $21M in quarter; net loss expected; reliance on trial success.”

No approved products and history of losses

“The Company has experienced net losses and negative cash flows from operations since its inception and has relied on its ability to fund its operations primarily through public or private equity or debt financings, collaboration arrangements, and other sources.” · word for word

Dependence on collaboration agreements

“We depend on strategic partnerships and collaboration arrangements for the development and commercialization of certain of our product candidates in certain indications or geographic territories, and if these arrangements are unsuccessful or are terminated, this could result in delays and other obstacles in the development, manufacture or commercialization o”

Clinical and regulatory uncertainty

“The regulatory approval process for novel product candidates such as ours is particularly uncertain, and our product candidates could fail to receive regulatory approval from the U.S. Food and Drug Administration (FDA) or a comparable foreign regulatory authority for many reasons” · word for word

Potential dilution from increased share authorization for equity incentives

“to increase the maximum number of shares available under such plan by an additional 7,000,000 shares.” · word for word

Clinical-stage biotech with no approved products; reliance on successful clinical trials and regulatory approvals.

“Company is clinical-stage; FT819 is investigational; no revenue from product sales mentioned.”

Cash runway into 2028 provides buffer but still dependent on future financing if milestones are delayed.

“Operating runway extended into 2028; no specific cash balance disclosed.”

No Product Revenue / Clinical Stage

“The Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated any revenues from any sales of its therapeutic product candidates.” · word for word

Cash Burn / Funding Dependency

“For the three months ended March 31, 2026, the Company incurred a net loss of $31.2 million and negative cash flows from operations of $30.8 million.” · word for word

Dependence on Collaboration Partner

“The Company will continue to receive committed funding under the joint development plan from Ono through June 2026.” · word for word

Clinical Development Risk

“Our product candidates and programs represent novel therapeutic approaches to treating disease, and our product candidates may fail to demonstrate the safety, potency, durability, and efficacy necessary to support further development or commercialization” · word for word

Funding Risk

“Development of our product candidates will require substantial additional funding, which, if available, may cause dilution to our stockholders, and without which we will be unable to complete preclinical or clinical development of, or obtain regulatory approval for, our product candidates.” · word for word

Regulatory Approval Uncertainty

“The regulatory approval process for novel product candidates such as ours is particularly uncertain, and our product candidates could fail to receive regulatory approval from the FDA or a comparable foreign regulatory authority for many reasons” · word for word

Manufacturing Complexity

“The manufacture and distribution of our product candidates is complex and subject to a multitude of risks.” · word for word

Competition

“We face significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively” · word for word

Clinical-stage biotech with no approved products; reliance on trial success.

“Clinical-stage biopharmaceutical company... no approved products.”

Small patient numbers in early-stage trials; results may not be reproducible.

“First SSc patient... one IIM patient... 15 SLE patients.”

Clinical-stage company with no approved products; reliance on pipeline success and regulatory approvals.

“clinical-stage biopharmaceutical company” · word for word

Small patient sample size (10 patients) limits statistical significance of clinical data.

“Updated Phase 1 data were presented for 10 patients” · word for word

Clinical-stage biotech with no approved products

“We have not yet obtained regulatory approval for any of our product candidates or generated any revenues from therapeutic product sales.” · word for word

Dependence on Ono collaboration for revenue

“Our revenues have been derived from collaboration agreements and government grants.” · word for word

Novel technology regulatory uncertainty

“To date, no iPSC-derived therapeutic product candidates have been approved in the United States or worldwide.” · word for word